ST-4PC聚合物糊剂药物制剂用于前列腺癌瘤内治疗
本研究开发了含多西他赛(dtx)与比卡鲁胺(bic)的可注射聚合物糊剂ST-4PC,用于前列腺癌(PCa)影像引导局灶治疗,并评估其体外释放特性及体内毒性与疗效。体外显示药物持续稳定释放,14天释放50% dtx与20% bic;体内无全身毒性,原位异种移植模型中1%/4% dtx/bic显著抑制肿瘤体积、血清PSA与生物发光。
要点
- ST-4PC可持续稳定释放dtx与bic,14天释放50% dtx和20% bic
- 原位模型中1%/4% dtx/bic显著降低肿瘤体积、PSA与生物发光
- 皮下模型出现dtx剂量依赖性局部副作用,提示其评估局限
核心结论
- ST-4PC影像引导局灶治疗在体内展现抑制PSA进展与原位肿瘤生长的作用且无明显毒性,值得进一步临床评估。
研究设计与样本
- 体外用高效液相色谱评估药物释放;小鼠与大鼠评估空白及载药ST-4PC的体内毒性;LNCaP皮下与原位异种移植模型评估抑瘤效果。
主要发现
- ST-4PC持续稳定释放药物,14天释放50% dtx与20% bic。
- 无全身毒性;皮下模型出现dtx剂量依赖性局部副作用,原位模型未见。
- 皮下模型中0.1%/4%与0.25%/4% dtx/bic显著降低PSA进展,但对肿瘤体积无显著抑制。
- 原位模型中1%/4% dtx/bic显著降低肿瘤体积、血清PSA与生物发光;与DMSO溶解药物相比ST-4PC显著延迟肿瘤生长。
临床怎么用
- 提示ST-4PC可作为PCa影像引导局灶治疗的候选制剂,需进一步临床研究验证。
局限性
- 皮下模型出现局部副作用而原位模型未见,说明皮下模型评估局部细胞毒性治疗存在局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Focal therapy has emerged as a treatment option for low- to intermediate-risk localized prostate cancer (PCa) patients, to balance the risks for urinary and sexual morbidity of radical treatment with the psychological burden of active surveillance. In this context, we developed ST-4PC, an injectable, polymeric paste formulation containing docetaxel (dtx) and bicalutamide (bic) for image-guided focal therapy of PCa. The objective of this work was to evaluate the in vitro characteristics and in vivo toxicity and efficacy of ST-4PC. MATERIAL AND METHODS: In vitro drug release was evaluated using high-performance liquid chromatography. In vivo toxicity of blank- and drug-loaded ST-4PC was assessed in mice and rats. Tumor growth inhibition was evaluated in LNCaP subcutaneous (s.c.) and LNCaP-luc orthotopic xenograft models. Using the s.c. model, mice were monitored weekly for weight loss, tumor volume (TV) and serum PSA. For the orthotopic model, mice were additionally monitored for bioluminescence as measure of tumor growth. RESULTS: ST-4PC demonstrated a sustained and steady release of incorporated drugs with 50% dtx and 20% bic being released after 14 days. While no systemic toxicity was observed, dose-dependent local side effects from dtx developed in the s.c. but not in the orthotopic model, illustrating the limitations of s.c. models for evaluating local cytotoxic therapy. In the s.c. model, 0.1%/4% and 0.25%/4% dtx/bic ST-4PC paste significantly reduced PSA progression, but did not have a significant inhibitory effect on TV. ST-4PC loaded with 1%/4% dtx/bic significantly reduced TV, serum PSA, and bioluminescence in the orthotopic xenograft model. Compared with drugs dissolved in DMSO, ST-4PC significantly delayed tumor growth. CONCLUSION: Image-guided focal therapy using ST-4PC demonstrated promising inhibition of PSA progression and orthotopic tumor growth in vivo without significant toxicity, and warrants further clinical evaluation.
引用
- Kesch C, Schmitt V, Bidnur S, et al. A polymeric paste-drug formulation for intratumoral treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2019. PMID: 31767941. doi:10.1038/s41391-019-0190-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。